<DOC>
	<DOC>NCT02373072</DOC>
	<brief_summary>This is a study with two sequential cohorts, each with three treatment periods. Single doses of PF-06649751 will be tested in this study, starting at a low dose and escalating to a dose projected to be under the current limits for drug concentration. Each cohort will aim to achieve approximately 9 completers. Primary endpoint is safety and tolerability, secondary endpoint is MDS-UPDRS part III.</brief_summary>
	<brief_title>A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Trimethobenzamide</mesh_term>
	<criteria>LDOPAresponsiveness Hoehn &amp; Yahr Stage IIIII inclusive Experiencing motor fluctuations Stable daily dose of LDOPA of at least 300 mg Females on nonchildbearing potential and male subjects History of troublesome dyskinesias History of surgical intervention for Parkinson's disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pakinson's Disease, Movement Disorders</keyword>
</DOC>